January 24, 2019
Janssen Biotech to work with private company Philogen on molecule-based therapeutics
Philogen S.p.A., a privately-owned biotechnology company, today announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech to discover new small molecule-based therapeutics utilizing Philochem’s novel lead-generation technologies.